Nocturna

Quick links to important sections

Nocturna

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nocturna

What is Nocturna? (Overview)

Property Description
Active ingredient Desmopressin acetate
Form Sublingual Tablet (Lyophilisate)
Pharmacological class Vasopressin Analog
Common use Reducing nighttime urine volume
Origin Synthetic Peptide

What Type of Medicine is Nocturna?

Nocturna is a prescription medication whose active ingredient is desmopressin, a synthetic copy of the naturally occurring Antidiuretic Hormone (ADH) found in the human body. The drug is classified as an antidiuretic hormone analog. The active ingredient is a synthetic peptide, meaning it is chemically manufactured to mimic the specific protein structure of the natural hormone.

This formulation is clinically recognized for its high selectivity, concentrating its effect on water retention in the kidneys while exhibiting minimal influence on other hormonal systems. This design differentiates it from the natural hormone, making it a targeted therapeutic agent.


Understanding the Form and Composition

Nocturna is provided as a unique, rapidly dissolving sublingual tablet (lyophilisate), designed to be placed and absorbed directly under the tongue. This specialized dosage form is a key distinguishing feature, allowing the active ingredient, desmopressin acetate, to enter the bloodstream efficiently via the sublingual route of administration. The sublingual route helps the drug bypass initial metabolism for more predictable absorption. The product is a single-entity drug, focusing its composition on the core therapeutic purpose.


What is the General Goal of Treatment?

The primary goal of taking Nocturna is to reduce the volume of urine the kidneys produce during the night in adults. By acting as an antidiuretic, the medicine signals the kidneys to conserve water effectively, leading to a decrease in the amount of fluid passed to the bladder during rest. The general therapeutic purpose of this action is to decrease the frequency of nighttime urination, thereby supporting longer, uninterrupted periods of sleep.

What side effects are possible with Nocturna?

Possible Side Effects and Safety Information

The safety profile of Nocturna (desmopressin) is fundamentally characterized by the risk of hyponatremia (low blood sodium), which is the most significant adverse reaction documented in official regulatory labeling. This risk stems directly from the medication's function as an antidiuretic, causing water retention.

Frequency and System-Organ Classes

Adverse reactions are formally categorized by frequency and the body system affected, based on regulatory classifications:

  • Common (occurring in 1 out of 100 to less than 1 out of 10 patients): These often involve the Nervous System (headache, dizziness) and Gastrointestinal Disorders (nausea, abdominal pain, diarrhea, dry mouth). Hyponatremia itself is listed as a common metabolic disorder.
  • Uncommon (occurring in 1 out of 1,000 to less than 1 out of 100 patients): These include sleeping difficulties such as insomnia and somnolence, as well as general weakness or asthenia.

Serious Adverse Reactions and Risk Timing

The most serious safety concern is severe hyponatremia, which can progress to neurological complications such as seizures or coma, as detailed in official warnings. Regulatory data indicates that the risk of developing hyponatremia is highest after three days of dosing, necessitating required serum sodium monitoring during the initial weeks of treatment.

Population-Specific Safety Constraints

Safety documents list specific constraints for certain populations. The medicine is contraindicated in patients with moderate to severe renal impairment and those with a history of hyponatremia or uncontrolled hypertension. Older adults (over 65 years) and women are noted in regulatory information to be at an increased risk of hyponatremia compared to other groups.

Overdose and Emergency Response

Overdose and when to seek help

The core risk associated with Nocturna overdose is the potentiation of its antidiuretic effect, leading to water intoxication and severe symptomatic hyponatraemia (low serum sodium). Documented clinical manifestations of this metabolic imbalance include headache, nausea, vomiting, confusion, dizziness, weight gain, and muscle cramps. Overdose is officially classified by regulators as a condition that can lead to life-threatening neurological complications, including seizures, coma, respiratory arrest, and cerebral edema.

Immediate medical help is required upon the appearance of any signs of hyponatraemia or water intoxication. The official instruction is to seek emergency medical attention and immediately interrupt the treatment. Management measures described in regulatory documents are strictly supportive, focusing on the urgent and strictly enforced restriction of fluid intake and individualized treatment to correct the sodium imbalance, as no specific antidote is known.

Elderly patients and individuals whose serum sodium levels are already in the lower range of normal are specifically documented as having an increased risk of developing severe hyponatraemia following overdose exposure.

Therapeutic Uses of Nocturna

What Nocturna treats: Main Uses and Benefits

Managing Nocturia Driven by Excessive Nighttime Urine Volume

Nocturna is applied in the therapeutic domain of urology to address the condition of nocturia, or the necessity to wake up during the night to pass urine, specifically when this is caused by nocturnal polyuria. The medication is used to address underlying symptoms related to increased urine output that interfere with daily functioning. This means the treatment is relevant when symptoms are driven by the kidneys producing an abnormally high volume of urine during sleep, rather than solely by bladder storage issues. The primary therapeutic purpose is generally considered to be the moderation of nocturnal urine volume, which helps with easing the frequency of voiding.

The medication is commonly used across conditions presenting with disruptive symptom manifestations, including the supportive management of nocturia and conditions where excessive nocturnal urine output is a key feature in adults.

“The symptomatic relief associated with managing this functional stress may support patients during difficult episodes by easing distress.”

Enhancing Sleep Continuity and Patient Comfort

The medication may provide supportive relief in the domain of sleep medicine, helping with maintaining functional stability related to rest. By reducing the number of times a patient is compelled to wake up and urinate, it may assist with easing the overall symptom load related to sleep disruption and its associated discomfort. This symptomatic relief supports general well-being during symptomatic phases, which is often a key concern for adults whose sleep is chronically disturbed by the need to void frequently.

Quick Fact: Symptomatic Focus The medication is relevant for easing symptoms that cluster into patterns requiring supportive management, specifically symptoms that interfere with daily functioning, such as frequent nocturnal awakenings.

Regulatory References

  1. NIH MedlinePlus overview of Desmopressin

Eligibility and Restrictions for Use

Who Can and Cannot Use Nocturna?

Eligibility for Nocturna (desmopressin acetate) is strictly defined by regulatory documents, focusing primarily on age, kidney function, and the risk of low sodium levels (hyponatremia).

Populations that Must Not Use Nocturna (Contraindications)

Official labeling specifies that this medicine is contraindicated for several groups:

  • Patients with hyponatremia (low serum sodium) or a history of this condition.
  • Individuals with moderate to severe renal impairment (kidney function below a creatinine clearance of 50 mL/min).
  • Those with known hypersensitivity to desmopressin or any component of the formulation.
  • Patients with cardiac insufficiency (heart failure) or those taking certain medications, such as loop diuretics.

Age and Special Population Eligibility

Age Group Eligibility Status Restriction/Condition
Adults Eligible Approved for the nocturia indication (generally ge 18 years).
Pediatric Patients Not Established Not eligible for the nocturia indication (generally < 18 years).
Older Adults Restricted Use Requires frequent monitoring of serum sodium due to increased risk of hyponatremia.

Use during pregnancy is generally under Category B (use only if clearly needed), and caution is advised when the medicine is administered to a nursing woman, as defined by official regulatory status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Nocturna is primarily defined by the pharmacodynamic effect—an additive risk of hyponatremia (low serum sodium) due to increased water retention. Regulatory documentation notes that desmopressin is a synthetic peptide not significantly metabolized by the Cytochrome P450 system; therefore, pharmacokinetic interactions are not documented as the basis for restrictions.

Absolute Prohibitions

Official regulatory labels designate co-administration with the following drug classes as strictly contraindicated due to the severe, additive risk of hyponatremia:

  • Loop Diuretics
  • Systemic or Inhaled Glucocorticoids (Steroids)

Use with Increased Monitoring

The simultaneous use of Nocturna with other medications that affect water and electrolyte balance requires increased monitoring of serum sodium. This includes classes such as Selective Serotonin Re-uptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opiate Analgesics, Chlorpromazine, Lamotrigine, and Carbamazepine.

Regulatory Constraints

Constraint Type Official Regulatory Statement
Timing-based Rule Fluid intake must be restricted from one hour before administration until eight hours after.
Substance Avoidance Drinks containing alcohol or caffeine must be avoided before bedtime.
Population Note Patients aged 65 years and older require more frequent serum sodium monitoring when taking concomitant hyponatremia-risk medications.

This structure establishes formal constraints and mandatory monitoring requirements documented in regulatory labeling to manage the potential for additive pharmacodynamic effects.

Mechanism of Action

Selective Agonism and V2 Receptor Activation

Nocturna's action begins by serving as a highly selective agonist at the Vasopressin V2 Receptor (V2R), which is situated on the principal cells of the renal collecting ducts. This targeted binding initiates a specific intracellular signaling cascade within the kidney that is focused on the renal mechanism for fluid conservation.


Modulation of the Aquaporin Water Channel System

The molecular cascade, driven by second messengers, leads to the chemical modification and subsequent rapid insertion of Aquaporin-2 ( AQP-2) water channels into the cell membrane . This physical opening of water channels increases the cell's permeability to water, thereby diverting water from the forming urine back into the systemic circulation.


Resulting Antidiuresis and Water Conservation

The final physiological consequence of this targeted mechanism is a state of antidiuresis. By conserving free water, the kidney produces a highly concentrated urine with a reduced total volume, resulting in the physiological effect of decreased fluid output.

Dosage and Administration Information

How to Use Nocturna: Official Administration Guidelines

The use of Nocturna (desmopressin sublingual tablet) for nocturia is governed by a specific administration protocol.

Element Official Instruction
Route of administration Sublingual (under the tongue).
Dosing schedule Fixed Gender-Specific Dose: 27.7 μg once daily for adult women; 55.3 μg once daily for adult men.
Frequency and timing Once daily, administered exactly 1 hour before bedtime.
Timing in relation to meals Should be administered without food, as ingestion with meals may reduce the antidiuretic effect.
Age-group administration rules Older Adults (ge 65 years): Dose increases beyond the initial gender-specific dose are not recommended.
Missed-dose rules If a dose is missed, it should not be taken later that night. The patient must wait for and take the next scheduled dose.
Special procedural conditions Mandatory Fluid Restriction: Fluid intake must be limited to a minimum from 1 hour before administration until 8 hours after the dose.

Resulting Procedural Structure

Official step sequence:

  • The tablet must be placed under the tongue and allowed to dissolve completely; it must not be chewed, swallowed, or taken with water.
  • The dose must be taken one hour before bedtime on an empty or near-empty stomach.
  • Fluid intake must be strictly limited starting one hour before the dose until the following morning.

Connection to the overall use protocol: The use protocol defines a once-daily, sublingual administration with a precise timing relative to sleep, requiring mandatory fluid restriction. This approach ensures consistent use within the limits defined by the gender-specific, fixed-dose regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nocturna

Evidence for Use in Nocturia Due to Nocturnal Polyuria

Nocturna was studied for adults with frequent nighttime urination (nocturia) that is caused by the kidneys producing too much urine overnight (nocturnal polyuria). The primary evidence consists of short-term (up to 3-month) Randomized, Double-Blind, Placebo-Controlled Trials (RCTs) that were used in research examining how symptoms change over time. These studies were used in research exploring how symptoms change over defined time intervals, comparing the active medicine group to the placebo group.

Researchers utilized RCTs to examine outcomes related to physical discomfort. They monitored outcomes related to functional imbalance, primarily focusing on measurements of nocturnal urine volume and the number of nocturnal voids. Studies report how symptoms evolved in the observed populations, and research describes changes measured during the study period, including the mean number of nighttime voids and the measured duration of the first uninterrupted sleep period.


Long-Term Research and Follow-up Durations

Studies have explored short-term symptom changes, with the majority of pivotal trials having follow-up durations limited to around 3 months (12 weeks). Some evidence derived from settings with varying symptom burdens extends to intermediate-term periods, typically up to 6 or 12 months. This research provides insight into short-term changes and how symptoms may evolve in the observed populations over longer intervals. Evidence is limited, and data for long-term outcomes extending consistently beyond one year remain insufficient. Long-term outcomes are not fully established, and research is ongoing to better characterize findings over longer durations.


Research Gaps and Areas of Uncertainty

Follow-up durations were limited in the pivotal trials, meaning data for long-term outcomes are still emerging. Comparative evidence is lacking for specific comparisons against all other existing drug and non-drug management strategies for nocturia. Findings were mixed regarding the size of the observed changes in some studies. This highlights what is known—and what is still uncertain—about the measured differences. The research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Nocturna (FAQ)


Q: How long does it usually take for Nocturna to start working?

Studies and official information indicate that the antidiuretic (water-retaining) effect of desmopressin typically begins within one hour after the sublingual tablet is administered. The maximum concentration of the medicine in the blood is usually reached within about two hours. This timing aligns with the administration instructions that specify taking the dose one hour before bedtime.


Q: How long does the effect of Nocturna last?

The duration of the intended antidiuretic action is closely linked to the official instructions for use. Regulatory documents require that fluid intake be restricted for at least 8 hours after taking the dose, which correlates with the period during which the medicine is actively reducing urine production.


Q: Can Nocturna cause dependency or addiction?

According to regulatory authorities, Nocturna (desmopressin) is not classified as a controlled substance. Therefore, the official product information does not include warnings or statements concerning the potential for addiction or dependency.


Q: Are there long-term side effects associated with Nocturna use?

Hyponatremia (low blood sodium) is the most serious adverse reaction. Regulatory information indicates that monitoring of sodium levels is often necessary, especially when treatment begins. The clinical trials used for approval for the nocturia indication were generally short-term, lasting up to three months, and data regarding outcomes for long-term use extending beyond one year are limited and still being characterized.


Q: Is Nocturna used for other conditions besides what is officially listed?

The active ingredient in Nocturna, desmopressin, is used in different formulations to treat several other conditions, such as central diabetes insipidus and primary nocturnal enuresis. However, this specific formulation of Nocturna is only approved and labeled for the reduction of nighttime urine volume in adults with nocturia.


Q: Does Nocturna interact with alcohol?

Official product documents state that drinks containing alcohol should be avoided before bedtime while using this medicine. Alcohol intake may reduce the medicine's overall effectiveness and may also increase the risk of developing hyponatremia (low blood sodium).


Q: What types of prescription medicines should not be taken with Nocturna?

Regulatory labeling strictly prohibits co-administration with certain drug classes due to the severe, additive risk of low blood sodium (hyponatremia). These include loop diuretics and systemic or inhaled glucocorticoids (steroids). Use with several other medications that affect water balance may require increased monitoring.


Q: Are there any foods or beverages that interact with Nocturna?

Studies on the sublingual tablet formulation indicate that consuming food near the time of administration can significantly reduce and delay the absorption of the active ingredient. For this reason, official administration guidelines specify taking the medicine without food, on a near-empty stomach.


Q: Has Nocturna been studied in people with chronic health conditions?

Official documents list certain chronic health issues, such as moderate to severe kidney impairment and cardiac insufficiency (heart failure), as contraindications for use. Patients with other serious chronic conditions were generally excluded from the main clinical trials, and monitoring is often required for existing conditions.


Q: Are there different strengths or dosages of Nocturna available?

According to regulatory documents, this medicine is available in two fixed, gender-specific doses for the nocturia indication. Regulatory documents list these specific doses but do not list other strengths for this specific use.


Q: Can Nocturna cause changes in mood or behavior?

While not listed as common side effects, adverse events related to mental status or mood can be symptoms of severe hyponatremia, the most serious side effect. These changes can include confusion, restlessness, and irritability, as noted in the official warnings section.


Q: Is Nocturna suitable for people with liver problems?

Pharmacokinetic data show that the active ingredient is not significantly broken down by the liver's primary enzyme system (Cytochrome P450). However, regulatory documents may caution or recommend close management by a healthcare professional for individuals with liver disease to address the potential for fluid and electrolyte imbalances.


Q: What happens if I take too much Nocturna?

Taking too much of this medicine can lead to symptoms of severe fluid retention and dangerously low blood sodium (hyponatremia). Signs of overdose may include headache, nausea, vomiting, sudden weight gain, and can progress to more serious neurological complications such as convulsions or coma.


Q: Is it better to take Nocturna in the morning or at night?

Official instructions mandate taking the medicine exactly one hour before bedtime. This specific timing is required because the drug is intended to reduce urine production precisely during the hours of sleep. The medicine is not administered in the morning.


Q: Are the side effects of Nocturna generally mild?

Many reported side effects, such as headache and dry mouth, are classified as common. However, the medicine carries a serious warning for hyponatremia (low blood sodium). While uncommon, hyponatremia is not considered mild and requires medical attention.


Q: What is the research evidence for Nocturna's use in younger adults?

Nocturna is approved for use in adults, generally defined as individuals aged 18 years and older. The clinical studies included the general adult population, with regulatory documents noting that older adults (over 65) require more frequent monitoring due to an increased risk of hyponatremia.


Q: Does Nocturna have any known interactions with herbal supplements?

Information on specific interactions with herbal supplements is not fully characterized in regulatory documents. Official guidelines recommend informing a healthcare provider about all medications, vitamins, and herbal products being used to ensure safe management.


Q: Why is Nocturna sometimes prescribed instead of other medications?

Nocturna is a targeted treatment that works by signaling the kidneys to conserve water and directly reduce the volume of urine produced at night. The decision to prescribe it is based on the healthcare provider’s assessment of the patient’s specific condition and overall health profile.


Q: What is the expected outcome of taking Nocturna?

The intended outcome, demonstrated in clinical studies, is the reduction of the amount of urine produced during the night. Researchers observed a measured decrease in the number of times patients had to wake up to urinate, alongside an increase in the duration of the first period of uninterrupted sleep.


Q: How is Nocturna processed by the body?

The medicine is designed to be absorbed directly into the bloodstream through the tissue under the tongue. Pharmacokinetic data show the active ingredient is mainly eliminated via the kidneys and is not significantly metabolized by the liver’s main enzyme system (Cytochrome P450).


Q: Can Nocturna be crushed or split?

The official administration instructions require that the rapidly dissolving tablet be placed and allowed to dissolve completely under the tongue. It must not be chewed, crushed, or swallowed, as this method of administration is crucial for proper absorption and effectiveness.


Q: Can Nocturna cause skin reactions or allergies?

Known hypersensitivity (an allergy) to the active ingredient or any component of the formulation is listed as a contraindication. While rare, cases of severe allergic reactions (anaphylaxis) have been reported with the active ingredient.


Q: Is Nocturna a controlled substance?

Nocturna (desmopressin) is a medicine that requires a prescription from a doctor, but it is not classified or scheduled as a controlled substance by regulatory bodies in the United States or other major international agencies.


Q: Do official sources mention the potential for rebound effects after stopping Nocturna?

Regulatory documents do not specifically use the term 'rebound effect' in the context of increased urination upon stopping the medicine. However, they emphasize the need for careful medical supervision and fluid monitoring after treatment is interrupted or discontinued.


Q: What happens if I stop taking Nocturna suddenly?

Official documentation states that treatment is interrupted if the desired clinical effect is not achieved or in the event of an acute illness (such as fever or severe vomiting/diarrhea). Regulatory documents detail rules for managing a missed dose, but provide no specific claims regarding the effects of sudden, long-term discontinuation.

How should Nocturna be stored and disposed of?

Storage and Disposal Requirements for Nocturna

Official labeling defines strict storage conditions for Nocturna (desmopressin acetate sublingual wafers) due to the medicine's sensitivity to moisture and temperature.

Requirement Category Official Regulatory Statement
Labeled storage temperature: Store at controlled room temperature, typically 20 C to 25 C.
Protection requirements: Must be kept in the original container and protected from light and moisture.
In-use stability (if applicable): If provided in a bottle, the product must be discarded 1 month after the first opening.
Child-protection storage: The medicine must be kept out of the sight and reach of children.
Disposal instructions: Unused or expired medicine must be disposed of in accordance with local requirements; consult a pharmacist for guidance.

These mandated conditions ensure the product remains stable and potent throughout its labeled shelf life and provide a clear protocol for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nocturna found in:

A-Z Index: